FAT1 and non-small cell lung carcinoma: As shown in Figure 1A, mutations in KEAP1 and FAT1 were significantly associated with a worse prognosis in NSCLC patients with NDB who received ICBs, suggesting that these genes may be negative indicators or are involved in the primary resistance to ICBs.